Charles River Laboratories International, Inc. CRL
337.52 USD +24.50 (+7.83%)
At closeNov 6, 2026, 5:40 PM EST
338.70 +1.18 +0.35%
After hours · Nov 6, 5:40 PM ET
316.61 Day range 339.94
149.93 52-week range 376.10
- YTD
- +69.20%
- 1 year
- +97.52%
Analyst view
Consensus: buy
Buy
Price target (mean) 318.87 -5.5% downside
Now 337.52
- Target (low)
- 145.00
- Target (mean)
- 318.87
- Target (high)
- 390.00
Ratings (0m) 17 14 buy · 2 hold · 1 sell
- Strong buy3
- Buy11
- Hold2
- Sell1
- Strong sell0
Recommendation trend
- This month 17
- 1 month ago 18
- 2 months ago 16
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 3.29 | 3.00 – 3.44 | 2.39 | +37.5% | 973.25M | -2.1% | 11 |
| Next quarter | 2.86 | 2.55 – 3.13 | 2.06 | +39.0% | 978.46M | -1.7% | 7 |
| Current year | 11.44 | 11.35 – 11.55 | 10.28 | +11.3% | 3.93B | -2.2% | 13 |
| Next year | 12.78 | 11.90 – 13.68 | 11.44 | +11.7% | 4.04B | +2.8% | 17 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | UBS | Maintained | Buy | Buy |
| Nov 5, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 5, 2026 | Barclays | Maintained | Overweight | Overweight |
| Nov 5, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Oct 13, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 28, 2026 | Jefferies | Maintained | Buy | Buy |
| Sep 25, 2026 | Deutsche Bank | Maintained | Buy | Buy |
| Sep 25, 2026 | TD Cowen | Maintained | Buy | Buy |
| Sep 25, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Sep 25, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 25, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 25, 2026 | Mizuho | Maintained | Neutral | Neutral |
| Sep 25, 2026 | Baird | Maintained | Outperform | Outperform |
| Sep 11, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Aug 10, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 7, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 6, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 6, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Aug 6, 2026 | JP Morgan | Upgrade | Neutral | Overweight |
| Jul 20, 2026 | CLSA | Downgrade | Outperform | Hold |
| Jul 13, 2026 | Mizuho | Maintained | Neutral | Neutral |
| Jul 9, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jun 17, 2026 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| May 29, 2026 | CLSA | Upgrade | Hold | Outperform |
| May 8, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 8, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 13, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Feb 25, 2026 | UBS | Maintained | Neutral | Neutral |
| Feb 20, 2026 | TD Cowen | Maintained | Buy | Buy |
